Mivacurium chloride
Mivacron (mivacurium chloride) is a small molecule pharmaceutical. Mivacurium chloride was first approved as Mivacron on 1992-01-22.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
296 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myeloid leukemia acute | D015470 | C92.0 | 42 | 40 | 16 | 2 | 1 | 85 | |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | C91.0 | 9 | 12 | 2 | 3 | — | 22 | |
| Promyelocytic leukemia acute | D015473 | C92.4 | — | — | 3 | 3 | — | 6 | |
| Neuromyelitis optica | D009471 | EFO_0004256 | G36.0 | — | 1 | — | 2 | — | 3 |
| Autoimmune diseases of the nervous system | D020274 | — | — | — | 1 | — | 1 | ||
| Transverse myelitis | D009188 | G37.3 | — | — | — | 1 | — | 1 | |
| Cns demyelinating autoimmune diseases | D020278 | EFO_1000870 | G37 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | C95 | 13 | 22 | 16 | — | 1 | 48 | |
| Prostatic neoplasms | D011471 | C61 | 6 | 19 | 8 | — | — | 29 | |
| Lymphoma | D008223 | C85.9 | 3 | 11 | 11 | — | 1 | 24 | |
| Myelodysplastic syndromes | D009190 | D46 | 11 | 11 | 5 | — | — | 23 | |
| Monocytic leukemia acute | D007948 | 7 | 6 | 1 | — | — | 12 | ||
| Myeloid leukemia | D007951 | C92 | 5 | 5 | 1 | — | — | 10 | |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 6 | 3 | — | — | 9 |
| Neoplasms | D009369 | C80 | 7 | 1 | 1 | — | — | 8 | |
| Large b-cell lymphoma diffuse | D016403 | C83.3 | 1 | 6 | 1 | — | — | 7 | |
| Eyelid neoplasms | D005142 | EFO_1000934 | 2 | 3 | 1 | — | — | 6 |
Show 12 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myelomonocytic leukemia acute | D015479 | C92.5 | 7 | 5 | — | — | — | 11 | |
| Erythroblastic leukemia acute | D004915 | EFO_1001257 | C94.0 | 7 | 5 | — | — | — | 11 |
| Megakaryoblastic leukemia acute | D007947 | C94.2 | 7 | 4 | — | — | — | 10 | |
| Non-hodgkin lymphoma | D008228 | C85.9 | 3 | 7 | — | — | — | 9 | |
| Biphenotypic leukemia acute | D015456 | C95.0 | 3 | 3 | — | — | — | 4 | |
| Mantle-cell lymphoma | D020522 | C83.1 | — | 3 | — | — | — | 3 | |
| Relapsing-remitting multiple sclerosis | D020529 | EFO_0003929 | — | 3 | — | — | — | 3 | |
| Basophilic leukemia acute | D015471 | C94.8 | 1 | 1 | — | — | — | 2 | |
| Eosinophilic leukemia acute | D015472 | 1 | 1 | — | — | — | 2 | ||
| Myelomonocytic leukemia chronic | D015477 | C93.1 | 1 | 1 | — | — | — | 2 |
Show 16 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | 1 | — | — | — | — | 1 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 1 | — | — | — | — | 1 |
| Head and neck neoplasms | D006258 | 1 | — | — | — | — | 1 | ||
| Sarcoma | D012509 | 1 | — | — | — | — | 1 | ||
| Multiple myeloma | D009101 | C90.0 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Drug therapy | D004358 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | MIVACURIUM CHLORIDE |
| INN | mivacurium chloride |
| Description | Mivacurium chloride (formerly recognized as BW1090U81, BW B1090U or BW1090U) is a short-duration non-depolarizing neuromuscular-blocking drug or skeletal muscle relaxant in the category of non-depolarizing neuromuscular-blocking drugs, used adjunctively in anesthesia to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.
|
| Classification | Small molecule |
| Drug class | quaternary ammonium derivatives: neuromuscular blocking agents |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | COc1cc2c(cc1OC)[C@@H](Cc1cc(OC)c(OC)c(OC)c1)[N+](C)(CCCOC(=O)CC/C=C/CCC(=O)OCCC[N+]1(C)CCc3cc(OC)c(OC)cc3[C@H]1Cc1cc(OC)c(OC)c(OC)c1)CC2.[Cl-].[Cl-] |
Identifiers
| PDB | — |
| CAS-ID | 106861-44-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL984 |
| ChEBI ID | — |
| PubChem CID | 71316 |
| DrugBank | DB01226 |
| UNII ID | 600ZG213C3 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 697 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
6,331 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more